Partnering Deals and Alliances with Big Biotech

  • March 2014
  • -
  • Currentpartnering
  • -
  • 529 pages

The Partnering Deals and Alliances with Big Biotech report provides the most comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty big biotech companies.

Partnering Deals and Alliances with Big Biotech provides the user with the following key benefits:

Detailed partnering activity profiles for each of the top 50 big biotech companies
Over 300 charts showing a company’s dealmaking activity since 2009, allowing quick identification potential partners
Partnering therapy focus revealed
Partnering activity since 2009 – number of deals per year
Full listing of partnering deals
Activity by deal type
Activity by industry sector
Activity by phase of development
Activity by technology type
Activity by therapeutic area
Comprehensive access to over 1,500 partnering deals as recorded at Current Agreement, together with contract documents if available
Insight into the terms included in a partnering agreement, together with real world clause examples, via contract documents
Understand the key deal terms the company has agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

The Partnering Deals and Alliances with Big Biotech report provides the most comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty big biotech companies.

This premier report provides all the information you require to better understand big biotech partnering.

One of the key aspects of partnering is finding those companies that are potential candidates for the development and commercialization of the next generation of therapies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.

Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company’s business development objectives. Over 300 charts allow quick understanding of each big biotech companies dealmaking trends over the last four years.

This report contains over 1,500 links to online copies of actual partnering deals as recorded at Current Agreement, together with contract documents if submitted to the Securities Exchange Commission by big biotech and their partners.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of big biotech’s dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading big biotech companies based on 2012 pharmaceutical revenues and dealmaking activity since 2009.

Chapter 3 reviews the top partnering and M&A deals of 2009-2014 according to reported deal size.

Chapter 4 provides a summary on best practice on how to submit an opportunity to big biotech, to ensure building of relationships and to obtain a prompt assessment and response from the business development function of the prospective partner.

Chapter 5 lists forthcoming partnering events where valuable face to face meetings with big biotech provide a highly effective means of obtaining interest in novel opportunities. These events are where dealmaking gets initiated through numerous back to back meetings.

The main body of the report is provided in chapter 6. In-depth profiles of every big biotech company provide everything required to assess the suitability of a company as a prospective partner. Each profile includes a company overview, partnering activity according to deal type, phase of development, therapy area and technology type.

Each company profile provides a comprehensive listing of deal records available at Current Agreements, each of which links direct to an online copy of the actual deal record plus contract document if filed with the SEC.

One of the key aspects of partnering is conducting due diligence on a partner to determine under what terms a prospective partner agrees to a partnering relationship.

Understanding the flexibility of a prospective partners’ negiotated deals terms provides critical insight into the negotiation process in termsof what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This data driven report contains over 1,500 links to online copies of actual deal records at Current Agreements and contract documents, where submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

In addition, contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

In summary, the report provides the reader with the tools necessary to make successful contact with the right big biotech partners effectively and efficiently.

Key benefits

Partnering Deals and Alliances with Big Biotech provides the user with the following key benefits:

Detailed partnering activity profiles for each of the top 50 big biotech companies
Over 300 charts showing a company’s dealmaking activity since 2009, allowing quick identification potential partners
Partnering therapy focus revealed
Partnering activity since 2009 – number of deals per year
Full listing of partnering deals
Activity by deal type
Activity by industry sector
Activity by phase of development
Activity by technology type
Activity by therapeutic area
Comprehensive access to over 1,500 partnering deals as recorded at Current Agreement, together with contract documents if available
Insight into the terms included in a partnering agreement, together with real world clause examples, via contract documents
Understand the key deal terms the company has agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Partnering Deals and Alliances with Big Biotech is intended to provide the reader with an in-depth understanding of the partnering activities of the leading fifty big biotech companies worldwide, enabling the effective assessment and selection of partners of choice, based on the latest knowledge of a company’s partnering.

Partnering Deals and Alliances with Big Biotech includes:

Detailed company profiles for each of the top 50 big biotech companies, including:
Partnering interests and indications
Partnering activity since 2009
Partner companies since 2009
Partnering activity since 2009 by:
Partner company
Deal type
Industry sector
Stage of development
Technology type
Therapy area
Over 300 charts showing the dealmaking activity of each company since 2009
The tools to enable effective and efficient preparation for partnering negotiation with big biotech
1,500 partnering deals as recorded at Current Agreement, together with contract documents if available
The leading M&A and partnering deals by value 2009-2014

The Partnering Deals and Alliances with Big Biotech report also provides comprehensive access to available contract documents for each of the fifty big biotech companies.

Analyzing actual company agreements allows assessment of the following:

What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subscontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Partnering Deals and Alliances with Big Pharma provides the user with the following key benefits:

Detailed partnering activity profiles for each of the top 50 big pharma companies
Over 300 charts showing a company’s dealmaking activity since 2009, allowing quick identification potential partners
Partnering therapy focus revealed
Partnering activity since 2009 – number of deals per year
Full listing of partnering deals
Activity by deal type
Activity by industry sector
Activity by phase of development
Activity by technology type
Activity by therapeutic area
Comprehensive access to over 3,000 partnering deals as recorded at Current Agreement, together with contract documents if available
Insight into the terms included in a partnering agreement, together with real world clause examples, via contract documents
Understand the key deal terms the company has agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table Of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Big biotech top 50 dealmaking activity

2.1. Introduction
2.2. Big biotech partnering over the years
2.4. Big biotech partnering by deal type
2.6. Big biotech partnering by stage of development
2.7. Big biotech partnering by technology type
2.8. Big biotech partnering by therapy area
2.9. Big biotech MandA over the years

Chapter 3 - Top big biotech deals by value

3.1. Introduction
3.2. Big biotech partnering
3.3. Big biotech MandA

Chapter 4 - Submitting Opportunities to Big biotech

4.1. How to submit an opportunity
4.2. Opportunity submission template
4.3. Sending emails
4.4. Face to face at partnering events
4.5. Online submission forms

Chapter 5 - Forthcoming big biotech partnering events

5.1. Forthcoming events

Chapter 6 - Big Biotech Company Profiles

6.1. Introduction
6.2. Field definitions
6.3. Company profiles
3SBio
Acorda Therapeutics
Actelion
Alexion Pharmaceuticals
Alkermes
AMAG Pharmaceuticals
Amgen
Anika Therapeutics
Array Biopharma
Bavarian Nordic
Biocon
Biogen Idec
BioMarin Pharmaceuticals
Cangene
Celgene
CSL
Cubist
Dendreon
Elan
Emergent BioSolutions
Enzo Biochem
Galapagos
Genmab
Gilead Sciences
Grifols
Ipsen
Isis Pharmaceuticals
LFB Group
Medivation
Morphosys
Nektar Therapeutics
Novo Nordisk
NPS Pharmaceuticals
Onyx Pharmaceuticals
Optimer
PDL BioPharma
Questcor Pharmaceuticals
Regeneron Pharmaceuticals
Roche
SciClone Pharmaceuticals
Seattle Genetics
Shire
Spectrum Pharmaceuticals
Swedish Orphan Biovitrum
The Medicines Company
UCB
United Therapeutics
Vertex Pharmaceuticals
ViroPharma

Chapter 7 - Resources

Appendices
Appendix 1 - Deal type definitions
Appendix 2 - Example contract document
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form - Reports
Order Form - Therapy Reports
Order Form - Reports

TABLE OF FIGURES

Figure 1: Big biotech partnering 2009-2014
Figure 2: Big biotech - top 50 partnering activity 2009 to 2014
Figure 3: Big biotech deal frequency - 2009 to 2014
Figure 4: Big biotech partnering by deal type 2009-2014
Figure 5: Big biotech partnering by stage of development 2009-2014
Figure 6: Big biotech partnering by technology type 2009-2014
Figure 7: Big biotech partnering by therapy area 2009-2014
Figure 8: Big biotech MandA 2009-2014
Figure 9: Big biotech - top 50 MandA activity 2009-2014
Figure 10: Big biotech MandA deal frequency 2009-2014
Figure 11: Leading partnering deals by value, 2009-2014
Figure 12: Leading MandA deals involving big biotech by value, 2009-2014
Figure 13: Typical partnering opportunity submission template
Figure 14: Company profile template and definitions used in report
Figure 15: 3SBio Dealmaking frequency 2009-2014
Figure 16: 3SBio Partnering deals by type
Figure 17: 3SBio Partnering deals by industry sector
Figure 18: 3SBio Partnering deals by technology type
Figure 19: 3SBio Partnering deals by stage of development
Figure 20: 3SBio Partnering deals by therapy area
Figure 21: Acorda Therapeutics Dealmaking frequency 2009-2014
Figure 22: Acorda Therapeutics Partnering deals by type
Figure 23: Acorda Therapeutics Partnering deals by industry sector
Figure 24: Acorda Therapeutics Partnering deals by technology type
Figure 25: Acorda Therapeutics Partnering deals by stage of development
Figure 26: Acorda Therapeutics Partnering deals by therapy area
Figure 27: Actelion Dealmaking frequency 2009-2014
Figure 28: Actelion Partnering deals by type
Figure 29: Actelion Partnering deals by industry sector
Figure 30: Actelion Partnering deals by technology type
Figure 31: Actelion Partnering deals by stage of development
Figure 32: Actelion Partnering deals by therapy area
Figure 33: Alexion Pharmaceuticals Dealmaking frequency 2009-2014
Figure 34: Alexion Pharmaceuticals Partnering deals by type
Figure 35: Alexion Pharmaceuticals Partnering deals by industry sector
Figure 36: Alexion Pharmaceuticals Partnering deals by technology type
Figure 37: Alexion Pharmaceuticals Partnering deals by stage of development
Figure 38: Alexion Partnering deals by therapy area
Figure 39: Alkermes Dealmaking frequency 2009-2014
Figure 40: Alkermes Partnering deals by type
Figure 41: Alkermes Partnering deals by industry sector
Figure 42: Alkermes Partnering deals by technology type
Figure 43: Alkermes Partnering deals by stage of development
Figure 44: Alkermes Partnering deals by therapy area
Figure 45: AMAG Pharmaceuticals Dealmaking frequency 2009-2014
Figure 46: AMAG Pharmaceuticals Partnering deals by type
Figure 47: AMAG Pharmaceuticals Partnering deals by industry sector
Figure 48: AMAG Pharmaceuticals Partnering deals by technology type
Figure 49: AMAG Pharmaceuticals Partnering deals by stage of development
Figure 50: AMAG Pharmaceuticals Partnering deals by therapy area
Figure 51: Amgen Dealmaking frequency 2009-2014
Figure 52: Amgen Partnering deals by type
Figure 53: Amgen Partnering deals by industry sector
Figure 54: Amgen Partnering deals by technology type
Figure 55: Amgen Partnering deals by stage of development
Figure 56: Amgen Partnering deals by therapy area
Figure 57: Anika Therapeutics Dealmaking frequency 2009-2014
Figure 58: Anika Therapeutics Partnering deals by type
Figure 59: Anika Therapeutics Partnering deals by industry sector
Figure 60: Anika Therapeutics Partnering deals by technology type
Figure 61: Anika Therapeutics Partnering deals by stage of development
Figure 62: Anika Therapeutics Partnering deals by therapy area
Figure 63: Array Biopharma Dealmaking frequency 2009-2014
Figure 64: Array Biopharma Partnering deals by type
Figure 65: Array Biopharma Partnering deals by industry sector
Figure 66: Array Biopharma Partnering deals by technology type
Figure 67: Array Biopharma Partnering deals by stage of development
Figure 68: Array Biopharma Partnering deals by therapy area
Figure 69: Bavarian Nordic Dealmaking frequency 2009-2014
Figure 70: Bavarian Nordic Partnering deals by type
Figure 71: Bavarian Nordic Partnering deals by industry sector
Figure 72: Bavarian Nordic Partnering deals by technology type
Figure 73: Bavarian Nordic Partnering deals by stage of development
Figure 74: Bavarian Nordic Partnering deals by therapy area
Figure 75: Biocon Dealmaking frequency 2009-2014
Figure 76: Biocon Partnering deals by type
Figure 77: Biocon Partnering deals by industry sector
Figure 78: Biocon Partnering deals by technology type
Figure 79: Biocon Partnering deals by stage of development
Figure 80: Biocon Partnering deals by therapy area
Figure 81: Biogen Idec Dealmaking frequency 2009-2014
Figure 82: Biogen Idec Partnering deals by type
Figure 83: Biogen Idec Partnering deals by industry sector
Figure 84: Biogen Idec Partnering deals by technology type
Figure 85: Biogen Idec partnering deals by stage of development
Figure 86: Biogen Idec Partnering deals by therapy area
Figure 87: BioMarin Pharmaceuticals Dealmaking frequency 2009-2014
Figure 88: BioMarin Pharmaceuticals Partnering deals by type
Figure 89: BioMarin Pharmaceuticals Partnering deals by industry sector
Figure 90: BioMarin Pharmaceuticals Partnering deals by technology type
Figure 91: BioMarin Pharmaceuticals: Partnering deals by stage of development
Figure 92: BioMarin Pharmaceuticals Partnering deals by therapy area
Figure 93: Cangene Dealmaking frequency 2009-2014
Figure 94: Cangene Partnering deals by type
Figure 95: Cangene Partnering deals by industry sector
Figure 96: Cangene Partnering deals by technology type
Figure 97: Cangene Partnering deals by stage of development
Figure 98: Cangene Partnering deals by therapy area
Figure 99: Celgene Dealmaking frequency 2009-2014
Figure 100: Celgene Partnering deals by type
Figure 101: Celgene Partnering deals by industry sector
Figure 102: Celgene Partnering deals by technology type
Figure 103: Celgene Partnering deals by stage of development
Figure 104: Celgene Partnering deals by therapy area
Figure 105: CSL Dealmaking frequency 2009-2014
Figure 106: CSL Partnering deals by type
Figure 107: CSL Partnering deals by industry sector
Figure 108: CSL Partnering deals by technology type
Figure 109: CSL Partnering deals by stage of development
Figure 110: CSL Partnering deals by therapy area
Figure 111: Cubist Dealmaking frequency 2009-2014
Figure 112: Cubist Partnering deals by type
Figure 113: Cubist Partnering deals by industry sector
Figure 114: Cubist Partnering deals by technology type
Figure 115: Cubist Partnering deals by stage of development
Figure 116: Cubist Partnering deals by therapy area
Figure 117: Dendreon Dealmaking frequency 2009-2014
Figure 118: Dendreon Partnering deals by type
Figure 119: Dendreon Partnering deals by industry sector
Figure 120: Dendreon Partnering deals by technology type
Figure 121: Dendreon Partnering deals by stage of development
Figure 122: Dendreon Partnering deals by therapy area
Figure 123: Elan: Dealmaking frequency 2009-2014
Figure 124: Elan: Partnering deals by type
Figure 125: Elan Partnering deals by industry sector
Figure 126: Elan Partnering deals by technology type
Figure 127: Elan Partnering deals by stage of development
Figure 128: Elan Partnering deals by therapy area
Figure 129: Emergent BioSolutions: Dealmaking frequency 2009-2014
Figure 130: Emergent BioSolutions Partnering deals by type
Figure 131: Emergent BioSolutions Partnering deals by industry sector
Figure 132: Emergent BioSolutions: Partnering deals by technology type
Figure 133: Emergent BioSolutions Partnering deals by stage of development
Figure 134: Emergent BioSolutions Partnering deals by therapy area
Figure 135: Enzo Biochem Dealmaking frequency 2009-2014
Figure 136: Enzo Biochem Partnering deals by type
Figure 137: Enzo Biochem Partnering deals by industry sector
Figure 138: Enzo Biochem Partnering deals by technology type
Figure 139: Enzo Biochem Partnering deals by stage of development
Figure 140: Enzo Biochem Partnering deals by therapy area
Figure 141: Galapagos Dealmaking frequency 2009-2014
Figure 142: Galapagos Partnering deals by type
Figure 143: Galapagos Partnering deals by industry sector
Figure 144: Galapagos Partnering deals by technology type
Figure 145: Galapagos Partnering deals by stage of development
Figure 146: GalapagosPartnering deals by therapy area
Figure 147: Genmab: Dealmaking frequency 2009-2014
Figure 148: Genmab: Partnering deals by type
Figure 149: Genmab Partnering deals by industry sector
Figure 150: Genmab Partnering deals by technology type
Figure 151: Genmab Partnering deals by stage of development
Figure 152: Genmab Partnering deals by therapy area
Figure 153 Gilead Sciences: Dealmaking frequency 2009-2014
Figure 154: Gilead Sciences Partnering deals by type
Figure 155: Gilead Sciences: Partnering deals by industry sector
Figure 156: Gilead Sciences Partnering deals by technology type
Figure 157: Gilead Sciences Partnering deals by stage of development
Figure 158: Gilead Sciences Partnering deals by therapy area
Figure 159: Grifols Dealmaking frequency 2009-2014
Figure 160: Grifols Partnering deals by type
Figure 161: Grifols Partnering deals by industry sector
Figure 162: Grifols Partnering deals by technology type
Figure 163: Grifols Partnering deals by stage of development
Figure 164: Grifols Partnering deals by therapy area
Figure 165: Ipsen Dealmaking frequency 2009-2014
Figure 166: Ipsen Partnering deals by type
Figure 167: Ipsen Partnering deals by industry sector
Figure 168: Ipsen Partnering deals by technology type
Figure 169: Ipsen Partnering deals by stage of development
Figure 170: Ipsen Partnering deals by therapy area
Figure 171: Isis Pharmaceuticals: Dealmaking frequency 2009-2014
Figure 172: Isis Pharmaceuticals Partnering deals by type
Figure 173: Isis Pharmaceuticals Partnering deals by industry sector
Figure 174: Isis Pharmaceuticals Partnering deals by technology type
Figure 175: Isis Pharmaceuticals Partnering deals by stage of development
Figure 176: Isis Pharmaceuticals Partnering deals by therapy area
Figure 177: LFB Group Dealmaking frequency 2009-2014
Figure 178: LFB Group Partnering deals by type
Figure 179: LFB Group Partnering deals by industry sector
Figure 180: LFB Group Partnering deals by technology type
Figure 181: LFB Group Partnering deals by stage of development
Figure 182: LFB Group Partnering deals by therapy area
Figure 183: Medivation Dealmaking frequency 2009-2014
Figure 184: Medivation Partnering deals by type
Figure 185: Medivation Partnering deals by industry sector
Figure 186: Medivation Partnering deals by technology type
Figure 187: Medivation Partnering deals by stage of development
Figure 188: Medivation Partnering deals by therapy area
Figure 189: Morphosys Dealmaking frequency 2009-2014
Figure 190: Morphosys Partnering deals by type
Figure 191: Morphosys Partnering deals by industry sector
Figure 192: Morphosys Partnering deals by technology type
Figure 193: Morphosys Partnering deals by stage of development
Figure 194: Morphosys Partnering deals by therapy area
Figure 195: Nektar Therapeutics Dealmaking frequency 2009-2014
Figure 196: Nektar Therapeutics Partnering deals by type
Figure 197: Nektar Therapeutics Partnering deals by industry sector
Figure 198: Nektar Therapeutics Partnering deals by technology type
Figure 199: Nektar Therapeutics Partnering deals by stage of development
Figure 200: Nektar Therapeutics Partnering deals by therapy area
Figure 201: Novo Nordisk Dealmaking frequency 2009-2014
Figure 202: Novo Nordisk Partnering deals by type
Figure 203: Novo Nordisk Partnering deals by industry sector
Figure 204: Novo Nordisk Partnering deals by technology type
Figure 205: Novo Nordisk Partnering deals by stage of development
Figure 206: Novo Nordisk Partnering deals by therapy area
Figure 207: NPS Pharmaceuticals Dealmaking frequency 2009-2014
Figure 208: NPS Pharmaceuticals Partnering deals by type
Figure 209: NPS Pharmaceuticals Partnering deals by industry sector
Figure 210: NPS Pharmaceuticals Partnering deals by technology type
Figure 211: NPS Pharmaceuticals Partnering deals by stage of development
Figure 212: NPS Pharmaceuticals Partnering deals by therapy area
Figure 213: Onyx Pharmaceuticals Dealmaking frequency 2009-2014
Figure 214: Onyx Pharmaceuticals Partnering deals by type
Figure 215: Onyx Pharmaceuticals Partnering deals by industry sector
Figure 216: Onyx Pharmaceuticals Partnering deals by technology type
Figure 217: Onyx Pharmaceuticals Partnering deals by stage of development
Figure 218: Onyx Pharmaceuticals Partnering deals by therapy area
Figure 219: Optimer Dealmaking frequency 2009-2014
Figure 220: Optimer Partnering deals by type
Figure 221: Optimer Partnering deals by industry sector
Figure 222: Optimer Partnering deals by technology type
Figure 223: Optimer Partnering deals by stage of development
Figure 224: Optimer Partnering deals by therapy area
Figure 225: PDL BioPharma Dealmaking frequency 2009-2014
Figure 226: PDL BioPharma Partnering deals by type
Figure 227: PDL BioPharma Partnering deals by industry sector
Figure 228: PDL BioPharma Partnering deals by technology type
Figure 229: PDL BioPharma Partnering deals by stage of development
Figure 230: PDL BioPharma Partnering deals by therapy area
Figure 231: Questcor Pharmaceuticals Dealmaking frequency 2009-2014
Figure 232: Questcor Pharmaceuticals Partnering deals by type
Figure 233: Questcor Pharmaceuticals Partnering deals by industry sector
Figure 234: Questcor Pharmaceuticals Partnering deals by technology type
Figure 235: Questcor Pharmaceuticals Partnering deals by stage of development
Figure 236: Questcor Pharmaceuticals Partnering deals by therapy area
Figure 237: Regeneron Pharmaceuticals Dealmaking frequency 2009-2014
Figure 238: Regeneron Pharmaceuticals Partnering deals by type
Figure 239: Regeneron Pharmaceuticals Partnering deals by industry sector
Figure 240: Regeneron Pharmaceuticals Partnering deals by technology type
Figure 241: Regeneron Pharmaceuticals Partnering deals by stage of development
Figure 242: Regeneron Pharmaceuticals Partnering deals by therapy area
Figure 243: Roche/ Genentech Dealmaking frequency 2009-2014
Figure 244: Roche/ Genentech Partnering deals by type
Figure 245: Roche/ Genentech Partnering deals by industry sector
Figure 246: Roche/ Genentech Partnering deals by technology type
Figure 247: Roche/ Genentech Partnering deals by stage of development
Figure 248: Roche/ Genentech Partnering deals by therapy area
Figure 249: SciClone Pharmaceuticals Dealmaking frequency 2009-2014
Figure 250: SciClone Pharmaceuticals Partnering deals by type
Figure 251: SciClone Pharmaceuticals Partnering deals by industry sector
Figure 252: SciClone Pharmaceuticals Partnering deals by technology type
Figure 253: SciClone Pharmaceuticals Partnering deals by stage of development
Figure 254: SciClone Pharmaceuticals Partnering deals by therapy area
Figure 255: Seattle Genetics Dealmaking frequency 2009-2014
Figure 256: Seattle Genetics Partnering deals by type
Figure 257: Seattle Genetics Partnering deals by industry sector
Figure 258: Seattle Genetics Partnering deals by technology type
Figure 259: Seattle Genetics Partnering deals by stage of development
Figure 260: Seattle Genetics Partnering deals by therapy area
Figure 261: Shire Dealmaking frequency 2009-2014
Figure 262: Shire Partnering deals by type
Figure 263: Shire Partnering deals by industry sector
Figure 264: Shire Partnering deals by technology type
Figure 265: Shire Partnering deals by stage of development
Figure 266: Shire Partnering deals by therapy area
Figure 267: Spectrum Pharmaceuticals Dealmaking frequency 2009-2014
Figure 268: Spectrum Pharmaceuticals Partnering deals by type
Figure 269: Spectrum Pharmaceuticals Partnering deals by industry sector
Figure 270: Spectrum Pharmaceuticals Partnering deals by technology type
Figure 271: Spectrum Pharmaceuticals Partnering deals by stage of development
Figure 272: Spectrum Pharmaceuticals Partnering deals by therapy area
Figure 273: Swedish Orphan Biovitrum Dealmaking frequency 2009-2014
Figure 274: Swedish Orphan Biovitrum Partnering deals by type
Figure 275: Swedish Orphan Biovitrum Partnering deals by industry sector
Figure 276: Swedish Orphan Biovitrum Partnering deals by technology type
Figure 277: Swedish Orphan Biovitrum Partnering deals by stage of development
Figure 278: Swedish Orphan Biovitrum Partnering deals by therapy area
Figure 279: The Medicines Company Dealmaking frequency 2009-2014
Figure 280: The Medicines Company Partnering deals by type
Figure 281: The Medicines Company Partnering deals by industry sector
Figure 282: The Medicines Company Partnering deals by technology type
Figure 283: The Medicines Company Partnering deals by stage of development
Figure 284: The Medicines Company Partnering deals by therapy area
Figure 285: UCB Dealmaking frequency 2009-2014
Figure 286: UCB Partnering deals by type
Figure 287: UCB Partnering deals by industry sector
Figure 288: UCB Partnering deals by technology type
Figure 289: UCB Partnering deals by stage of development
Figure 290: UCB Partnering deals by therapy area
Figure 291: United Therapeutics Dealmaking frequency 2009-2014
Figure 292: United Therapeutics Partnering deals by type
Figure 293: United Therapeutics Partnering deals by industry sector
Figure 294: United Therapeutics Partnering deals by technology type
Figure 295: United Therapeutics Partnering deals by stage of development
Figure 296: United Therapeutics Partnering deals by therapy area
Figure 297: Vertex Pharmaceuticals Dealmaking frequency 2009-2014
Figure 298: Vertex Pharmaceuticals Partnering deals by type
Figure 299: Vertex Pharmaceuticals Partnering deals by industry sector
Figure 300: Vertex Pharmaceuticals Partnering deals by technology type
Figure 301: Vertex Pharmaceuticals Partnering deals by stage of development
Figure 302: Vertex Pharmaceuticals Partnering deals by therapy area
Figure 303: ViroPharma Dealmaking frequency 2009-2014
Figure 304: ViroPharma Partnering deals by type
Figure 305: ViroPharma Partnering deals by industry sector
Figure 306: ViroPharma Partnering deals by technology type
Figure 307: ViroPharma Partnering deals by stage of development
Figure 308: ViroPharma Partnering deals by therapy area
Figure 309: Online partnering resources
Figure 310: Deal type definitions
Figure 311: Collaborative RandD and license agreement between GlaxoSmithKline and Supergen, November 2009

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Clare

+1 339 368 6001

Purchase Reports From Reputable Market Research Publishers

Photomedicine: Technologies and Global Markets

Photomedicine: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • September 2014
  • by BCC Research

This BCC Research study provides a comprehensive analysis of the market of photomedicine. It addresses the drivers and limiters of the market and offers an exhaustive analysis of both drugs and medical ...

ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations

ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations

  • $ 4 995
  • Industry report
  • July 2014
  • by GBI Research

ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations Summary GBI Research has released the pharma report, “ADHD Therapeutics ...

Hospital Infection Therapeutics Market (Drug Type: Antibacterial, Antiviral and Antifungal Drugs; Infection Type) - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020

Hospital Infection Therapeutics Market (Drug Type: Antibacterial, Antiviral and Antifungal Drugs; Infection Type) - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020

  • $ 4 795
  • Industry report
  • September 2014
  • by Transparency Market Research

Hospital Infection Therapeutics Market (Drug Type: Antibacterial, Antiviral and Antifungal Drugs; Infection Type: Hospital-Acquired Pneumonia, Urinary Tract Infections, Gastrointestinal Disorders, Bloodstream ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.